SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:kth-205258"
 

Sökning: onr:"swepub:oai:DiVA.org:kth-205258" > Cytokine and antibo...

Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1

Gafvelin, G (författare)
Karolinska Institutet
Thunberg, Sarah, 1976- (författare)
Karolinska Institutet
Kronqvist, M (författare)
Karolinska institutet
visa fler...
Gronlund, H (författare)
Karolinska Institutet
Gronneberg, R (författare)
Karolinska Institutet
Troye-Blomberg, M (författare)
Karolinska institutet
Akdis, M (författare)
SIAF, switzerland
Fiebig, H (författare)
Allergopharma, Germany
Purohit, A (författare)
Hôpitaux Universitaires de Strasbourg, France
Horak, F (författare)
Medical University of Vienna, Austria
Reisinger, J (författare)
Medical University of Vienna, Austria
Niederberger, V (författare)
Medical University of Vienna, Austria
Akdis, C A (författare)
SIAF Switzerland
Cromwell, O (författare)
Allergopharma, Germany
Pauli, G (författare)
Hôpitaux Universitaires de Strasbourg, France
Valenta, R (författare)
Medical University of Vienna, Austria
van Hage, M (författare)
Karolinska Institutet
Thunberg, S (författare)
Karolinska Institutet
Akdis, CA (författare)
visa färre...
 (creator_code:org_t)
2005
2005
Engelska.
Ingår i: International Archives of Allergy and Immunology. - 1018-2438 .- 1423-0097. ; 138:1, s. 59-66
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Recently, recombinant hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, were used to treat birch-pollen-allergic patients in a double-blind, placebo-controlled, multi-centre immunotherapy study. The aim of this study was to evaluate the effects of vaccination with aluminium-hydroxide-adsorbed recombinant Bet v 1 derivatives versus placebo on T-cell, cytokine and antibody responses in a subgroup of patients. Methods: Blood was drawn from patients of the Swedish centre (n=27; rBet v 1 fragments: n=10; rBet v 1 trimer: n=8, and placebo-aluminium hydroxide: n=9) before the start and after completion of the treatment. PBMC were stimulated with rBet v 1 and analysed for cytokine (IL-4, IL-5, IL-10, IL-12, IL-13 and IFN-gamma)-secreting cells by ELISpot. Bet v 1-specific antibody levels in serum (IgG(1-4), IgE and IgA) were measured by ELISA. Skin prick tests with defined Bet v 1 concentrations were performed before and 10-11 months after the beginning of the study. Results: Bet v 1-specific IgG levels, consisting of IgG 1, IgG 2 and IgG 4, were significantly increased after treatment with recombinant allergen derivatives. Treatment with rBet v 1 trimer led to a significant (p<0.05) reduction of Bet v 1-reactive IL-5- and IL-13-producing cells, reflecting a reduced Th2 response. In addition, a decreased number of Bet v 1-reactive IL-4 producing (p=0.07) and an increase of IL-12-producing (p=0.06) cells was noted in the trimer-treated patients. In contrast to placebo, active treatment resulted in significantly reduced immediate-type skin reactions to Bet v 1 even 10-11 months after treatment. Conclusion: Vaccination with recombinant hypoallergenic Bet v 1 derivatives induces a Bet v 1-specific IgG response and leads to reduced skin reactivity in allergic patients. A reduction of Bet v 1-specific Th2 responses was observed in trimer-treated patients, which may reflect the intrinsic property of this allergen derivative. Copyright (C) 2005 S. Karger AG, Basel.

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy